VivoSeq
Other

Gingival Recession

0

Pipeline Programs

3

Active Trials

1

Companies Involved

Gingival Recession is an early-stage landscape with 0 programs across 1 company. The most active players are Zeliha Başak Çakır Erdil.

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

91/100

Attrition Rate

5/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

19

clinical trials

Completed10 · 53%
Unknown status5 · 26%
Recruiting2 · 11%
Withdrawn1 · 5%
Not yet recruiting1 · 5%

Trial Activity

19 trials

VCMX, PRF and SCTG Treatment in the Gingival Recessions
Completed··Phase 3·NCT07345520·60 enrolled
Treatment of Multiple Gingival Recessions
Completed·UUniversity of Sao Paulo·Phase 4·NCT02818855·15 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)